Who
Carsten Boess
Director
Company insider
Files Form 4 as: Director, Rocket Pharmaceuticals; Director, Atrium Therapeutics; Director, Avidity Biosciences; 10% owner, Kiniksa Pharmaceuticals International; SVP, Chief Financial Officer, Synageva Biopharma; Vice President, International, Insulet.
In numbers
- Trades disclosed
- 238
- Buys
- 1
- Sells
- 29
- Bought
- $118K
- Sold
- $17.9M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 3 Dec 2007
- Last trade
- 18 Jun 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —6,692 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,034 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,489 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —10,034 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —13,489 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —20,858 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,858 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —6,692 | filing |
News
No headline names them, or the companies they trade most, lately.